December 9 12.

MedImmune announced today that the results of three programs within the company expanded oncology pipeline at the American Society of Hematology 48th Annual Meeting will be presented, December 9 – 12, 2006 in Orlando, clinical program updates include interim results for potential cancer therapy targeting multiple myeloma and certain leukemias and lymphomas.

Inhibition of Hsp90 can broad therapeutic potential in the treatment of patients with solid tumors and blood cancers, including cancers, Infinity to other drugs.. About Hsp90 and IPI-504IPI-504 is a proprietary small molecule therapeutic drug candidates currently as part of a drug development and worldwide commercialization agreement between MedImmune and Infinity Pharmaceuticals, evaluated in preclinical studies, IPI-504 has potently and selectively inhibited Hsp90 thereby killing of cancer cells.The system is improvements include an increase in the sequence of reading Duration the other side 400 base pair. The outcome of are by sequencing solution more than 1 billion bases are produced per day. Other updates any concentrate on enhancements do it is experience to routinely sequence the human genome. These system new capabilities include improvement from the reagents and software that. The same hardware configuration, which is currently available and bought as the in this Agreement.. Fleet Roche Genome Sequencer FLX System is increased to 10 instrument at the Baylor College of Medicine.

Addition to sales contract, resequence Human Genome Sequencing Center and Rochester also extended their prior cooperation.

Web site U.S. Website. All trademarks is mentioned in this news release law the law.. For more information you can visitAbout Roche and Roche Divisionin Basel, Switzerland, Rochester world’s world’s leading research-focused health care company in the areas pharmaceuticals and diagnostics. As provider of innovative products and and services that for the early, prevention, diagnosis and treatment of disease, the Group contributes on a broad scale for improving the health and the quality of life. Roche is the the world important suppliers of diagnostics, the leader medicines for cancer and transplantation and a market leader in virology. Of the the pharmaceutical Division sales totaled 33.3 billion Indian Rupee and while the Diagnostics Division sales of 8.7 billion CHF. The Group employs about 75th 000 employees in 150 countries and with research and D agreements and strategic alliances with numerous partners, including majority interests in Genentech and Chugai.

Published by